TNFRSF8 and mycosis fungoides: However, in one of the studies, utilizing the maximum CD30 expression level (CD30max) of a minimum of 2 biopsies from different lesion morphology and site, CD30 expression <5% was associated with a significantly lower response rate, but not shorter progression-free survival or duration of response (DOR).9 An exploratory analysis of patients with MF in the phase III ALCANZA characterized patients as CD30min <10% (1 biopsy with <10% CD30 expression) or CD30min ≥10% (all biopsies with ≥10% CD30 expression).